Personal Finance

Why Celator Pharmaceuticals Shares Are Skyrocketing Today

Take Long View

Take Long View

I think there are plenty of reasons for investors in both of these companies to look upon this deal favorably. Celator's shareholders now have a five-bagger on their hands, an amazing performance for a company that has only been on the market for a handful of years.

Meanwhile Jazz's investors should also benefit over time since all signs point to Vyxoes being a winner. Jazz is also in a great position to launch the drug quickly should it win approval since it already has most of the commercial infrastructure in place to support a launch in the oncology space. Vyxeos also looks like a nice fit within the company's orphan disease focus, and with some industry experts forecasting that sales could grow to $900 million by 2020, it doesn't look like Jazz is overpaying.

Roughly 18.4% of Celator's shareholders have already agreed to the deal, which includes the company's executive officers and members of its board of directors, so the odds of the deal winning shareholder approval look quite high.

Jazz's shares currently trading hands for under 12 times next year's earnings estimates. If you believe this deal was a smart long-term move, it could be a good time to pick up a few shares.

A secret billion-dollar stock opportunity

The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Personal Finance Videos

    Growth in Separately Managed Accounts and Why They Are Attractive for Financial Advisors

    Nasdaq Dorsey Wright Client Portfolio Manager Andy Hyer discusses the growth in Separately Managed Accounts and why they are attractive for financial advisors.

    4 days ago

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More